To ensure consistent product quality and regulatory compliance, biologics manufacturers must maintain tight control over their analytical test methods. At Samsung Biologics, this imperative is addressed through a formal assay performance monitoring (APM) program, which is designed not only to track quality but also to predict and prevent risk. In this Q&A, Samsung Biologics offers expert insights into how APM strengthens method robustness and ensures regulatory compliance while laying the groundwork for the digital future of real-time monitoring. Regulatory guidelines include United States Pharmacopeia (USP) <1220>, which outlines a life cycle approach to analytical procedure validation, and International Council for Harmonisation (ICH) Q14, which provides international guidance on analytical procedure development and control strategies.
Introduction
Samsung Biologics developed an APM program to ensure that analytical testing methods remain reliable and consistent over time, performing in line with the originally validated state and historical data trends. The program is designed to reinforce method robustness, detect any drift in performance before it affects product quality or compliance, and uphold regulatory expectations. By continuously monitoring assay performance, the company can identify trends, flag potential issues early, and confirm that methods remain within predefined specifications. This proactive approach helps maintain product quality, minimize batch release delays, and strengthen overall regulatory compliance.
Q: How does the program align with relevant regulatory expectations?
A: Samsung Biologics designed its APM program in accordance with the principles outlined in USP <1220> and ICH Q14. These regulatory guidelines emphasize a life cycle approach to analytical procedure development and control. APM supports this approach by ensuring that validated analytical methods are continuously monitored for reliability, performance data are evaluated over time, and necessary corrective actions are taken when deviations are observed, thereby maintaining method robustness and meeting regulatory expectations.
Q: What are the main components of Samsung Biologics’ APM program, and how do you determine which assays to include?
A: The APM framework begins with the routine collection of performance data across validated analytical methods. The outputs of processes using these analytical methods are the only assays eligible for inclusion under Samsung Biologics’ internal procedures. Compendial methods governed by pharmacopeial standards are excluded since they are not subject to internal validation. Once collected, assay data are used for trend analysis to detect deviations or emerging issues, while invalid result rates are closely tracked as early indicators of potential problems with reagents, equipment, or execution. If anomalies are observed or thresholds are exceeded, corrective and preventive actions are initiated, and all findings are thoroughly documented. This systematic approach ensures both real-time insight and retrospective traceability.
Q: Are there any key indicators that trigger deeper laboratory investigations?
A: Indicators that may prompt a more in-depth investigation include test methods with invalid result rates that exceed predefined thresholds or exhibit unexpected performance trends. Such signals suggest potential issues in the analytical workflow and warrant immediate evaluation to determine the root cause, whether it is related to materials, the equipment, environment, or operator.
Q: Why does your program prioritize invalid rate monitoring?
A: Monitoring invalid rates is critical because high invalidation frequencies can delay batch release and indicate problems that compromise assay reliability. Issues such as degraded reagents, equipment malfunction, or procedural inconsistencies can drive up invalid rates. By routinely tracking this metric, Samsung Biologics can detect problems early and take corrective measures before the issues affect product release or quality.
Q: What are typical causes of high invalid rates, and how does the APM program address them?
A: High invalid rates may result from issues such as reagent instability, human error during assay execution, equipment wear, or uncontrolled environmental variables. The APM program detects these issues by continuously monitoring invalid rate data. When outliers or upward trends are observed, the system triggers investigations that lead to early interventions, thereby minimizing disruption to operations and reducing the risk of downstream quality issues.
Q: How does trend analysis enhance Samsung Biologics’ APM framework compared to relying solely on control chart violations?
A: Trend analysis is a central feature of Samsung Biologics’ APM strategy because it provides earlier and more nuanced insights into assay behaviors than control charts alone. While control charts use static thresholds, which may miss gradual shifts, trend analysis evaluates performance data over time, making it possible to detect subtle but consistent changes or recurring anomalies before they escalate into control limit violations. This proactive approach enables timely corrective actions, validates improvements, and strengthens continuous enhancement efforts, ultimately ensuring greater assay robustness and preventing surprises during batch testing.
Q: What software supports Samsung Biologics’ APM program, and how does it integrate with the broader digital infrastructure?
A: To support its APM activities, Samsung Biologics employs a GMP-validated software platform that is widely used across the global biopharma industry. The system enables secure data collection, centralized monitoring, and advanced analytics while ensuring compliance with regulatory requirements for accuracy and audit readiness. The company recognizes the importance of linking its APM program with broader enterprise systems, such as LIMS and QMS. Such integrations facilitate seamless data flows and provide end-to-end visibility across the manufacturing and quality functions.
Q: What are the limitations of manual monitoring, and how is Samsung Biologics moving toward real-time or automated APM?
A: Manual, periodic monitoring is labor-intensive and prone to human error, lacking the immediacy needed to detect anomalies as they occur. The use of manual monitoring can slow response times and reduce efficiency, especially in high-throughput or multi-client environments. To address these challenges, Samsung Biologics is investing in digital infrastructure and automation technologies that enable real-time monitoring. By reducing reliance on manual processes, the company aims to improve data accuracy, provide immediate feedback when issues arise, and build a fully automated framework that enhances data integrity, shortens response times, and strengthens overall operational efficiency.
Q: What impact will the shift to real-time or automated APM have on quality and efficiency, and what challenges come with this transition?
A: Moving toward real-time or automated APM is expected to significantly improve product quality and operational efficiency. The faster detection and resolution of issues will strengthen assay robustness, while automation will reduce repetitive manual tasks as well as enhance the accuracy and reliability of analytical results, ultimately supporting quicker batch release and greater confidence in manufacturing consistency. At the same time, Samsung Biologics faces the challenge of building a system that is scalable and adaptable to the diverse analytical requirements of clients. Creating such flexible infrastructure will demand careful planning and cross-functional collaboration to ensure that varied assay formats and workflows are accommodated without compromising control or functionality.
Q: How does this program reflect Samsung Biologics’ broader commitment to quality and innovation?
A: The APM initiative embodies Samsung Biologics’ dedication to delivering the highest standards of analytical rigor. By proactively monitoring method performance, adopting advanced software, and pursuing automation, the company reinforces its reputation as an innovator and leader in biologics manufacturing. The program also supports patient safety by ensuring that every test result guiding product release is reliable, reproducible, and in control.
Q: Looking ahead, do you see APM becoming a new industry standard?
A: As analytical methods become more complex and regulatory scrutiny intensifies, robust APM programs are poised to become essential across the industry. Samsung Biologics sees its current system not only as a compliance tool but also as a model for continuous improvement. By embedding APM in the core of its quality operations, the company is helping to define a new benchmark for analytical assurance in the biologics space.
